Is Trident Lifeline overvalued or undervalued?

As of 16 October 2025, the valuation grade for Trident Lifeline has moved from expensive to very expensive, indicating a significant increase in perceived valuation. The company is currently considered overvalued. Key ratios include a PE Ratio of 21.65, an EV to EBITDA of 18.24, and a ROE of 9.87%.
In comparison with its peers, Trident Lifeline's PE Ratio is notably lower than Sun Pharma's 34.69 but higher than Cipla's attractive valuation at 23.51. Additionally, while Trident's PEG Ratio stands at a low 0.26, indicating potential growth, it still reflects an expensive valuation relative to its peers. Recent stock performance shows that Trident has outperformed the Sensex over the past year, with a return of 8.91% compared to the Sensex's 2.41%, which may suggest investor confidence despite its high valuation.